$NMTR Hi all, I am having trouble copy and pasting the responses I received from Al Medwar: Laural Your message was forwarded to me regarding the timing of the VIBRANT study data. At this time, we have not changed our guidance on the first quarter timing of topline data for the vurolenatide phase 2 study in short bowel syndrome. However, as you know, COVID is having widespread impacts including staffing in healthcare facilities. We will be monitoring this closely over the coming weeks, and if the timing changes, we will make an announcement. Note, the duration of treatment for patients in the trial is 4 weeks (not 13 weeks), so patients beginning treatment now can still complete by the end of the quarter. See the study design outline below. I hope this is helpful.